VEGF/VEGFR Inhibitors

Aflibercept is a biopharmaceutical drug invented by Regeneron Pharmaceuticals, approved in the United States and Europe for the treatment of wet macular degeneration under the trade name Eylea, and for metastatic colorectal cancer as Zaltrap...Wikipedia

Manufacturer's Website: Zaltrap

Average retail cost: $1,600/vial

Ponatinib (trade name Iclusig) is an oral drug developed by ARIAD Pharmaceuticals for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL)...Wikipedia

Manufacturer's Website: Iclusig

Average retail cost: $5,500/vial

Vandetanib (INN, trade name Caprelsa) is an anti-cancer drug that is used for the treatment of certain tumours of the thyroid gland...Wikipedia

Manufacturer's Website: Caprelsa

Average retail cost: $6,600/vial

Ramucirumab (trade name Cyramza) is a fully human monoclonal antibody (IgG1) developed for the treatment of solid tumors...Wikipedia

Manufacturer's Website: Cyramza

Average retail cost: $6,700/vial

Pazopanib (trade name Votrient) is a potent and selective multi-targeted receptor tyrosine kinase inhibitor that blocks tumor growth and inhibits angiogenesis. It has been approved for renal cell carcinoma and soft tissue sarcoma by numerous regulatory administrations worldwide...Wikipedia

Manufacturer's Website: Votrient

Average retail cost: $11,250/month

Lenvatinib (trade name Lenvima) is an anti-cancer drug for the treatment of certain kinds of thyroid cancer, and potentially for other cancers as well. It was developed by Eisai Co. and acts as a multiple kinase inhibitor against the VEGFR1, VEGFR2 and VEGFR3 kinases...Wikipedia

Manufacturer's Website: Lenvima

Average retail cost: $14,800/month

Cabozantinib, sold under the brand-name Cabometyx and Cometriq, is a medication used to treat medullary thyroid cancer and a second line treatment for renal cell carcinoma among others...Wikipedia

Manufacturer's Website: Cometriq

Average retail cost: $15,100/month

Regorafenib (commercial name Stivarga) is an oral multi-kinase inhibitor developed by Bayer which targets angiogenic, stromal and oncogenic receptor tyrosine kinase (RTK). Regorafenib shows anti-angiogenic activity due to its dual targeted VEGFR2-TIE2 tyrosine kinase inhibition. Since 2009 it was studied as a potential treatment option in multiple tumor types...Wikipedia

Manufacturer's Website: Stivarga

Average retail cost: $15,400/month

Cabozantinib, sold under the brand-name Cabometyx and Cometriq, is a medication used to treat medullary thyroid cancer and a second line treatment for renal cell carcinoma among others...Wikipedia

Manufacturer's Website: Cabometyx

Average retail cost: $21,400/month

Sunitinib (marketed as Sutent by Pfizer) is an oral, small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor that was approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST) on January 26, 2006. Sunitinib was the first cancer drug simultaneously approved for two different indications...Wikipedia

Manufacturer's Website: Sutent

Average retail cost: $16,500/month

Sorafenib (co-developed and co-marketed by Bayer and Onyx Pharmaceuticals as Nexavar), is a kinase inhibitor drug approved for the treatment of primary kidney cancer (advanced renal cell carcinoma), advanced primary liver cancer (hepatocellular carcinoma), and radioactive iodine resistant advanced thyroid carcinoma...Wikipedia

Manufacturer's Website: Nexavar

Average retail cost: $16,800/month

Bevacizumab, sold under the trade name Avastin, is medication used to treat a number of types of cancers and a specific eye disease. For cancer it is given by slow injection into a vein and used for colon cancer, lung cancer, glioblastoma, and renal-cell carcinoma. For age-related macular degeneration it is given by injection into the eye...Wikipedia

Manufacturer's Website: Avastin

Average retail cost: $18,800/month